Clinical presentations of adult and pediatric SARS-CoV-2-positive cases in a community cohort, Nashville, Tennessee.

Clinical presentations of adult and pediatric SARS-CoV-2-positive cases in a community cohort, Nashville, Tennessee.
复制标题

DOI:
10.1002/jmv.27988
复制
发表时间:
2022-11
影响因子:
12.7
通讯作者:
Howard, Leigh M.
Howard, Leigh M.
中科院分区:
医学3区
文献类型:
--
作者:
Rankin, Danielle A.;Yanis, Ahmad;Talj, Rana;Howe, Harrison L.;Bloos, Sean M.;Fernandez, Kailee N.;Amarin, Justin Z.;Bruce, Mercedes;Salib, Seifein;Hargrave, Samarian;Chappell, James D.;Spieker, Andrew J.;Halasa, Natasha B.;Howard, Leigh M.

文献摘要

参考文献

相似文献

与成人相比,儿童严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疾病的患病率较低且病情较轻。然而,比较儿童和成人 SARS-CoV-2 感染的报道有限。作为对田纳西州纳什维尔 SARS-CoV-2 感染成人和儿童及其家庭接触者的纵向队列研究的一部分,我们比较了儿童和成人之间 SARS-CoV-2 感染的临床特征和结果。与成人相比,儿童更有可能无症状感染,且病程较短。不同年龄段临床表现的差异可能会影响特定症状的测试、筛查和管理算法。
Compared to adults, the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) illness in children has been lower and less severe. However, reports comparing SARS‐CoV‐2 infection among children and adults are limited. As part of our longitudinal cohort study of adults and children with SARS‐CoV‐2 infection and their household contacts in Nashville, Tennessee, we compared the clinical characteristics and outcomes of SARS‐CoV‐2 infections between children and adults. Children were more likely to be asymptomatically infected and had a shorter illness duration compared to adults. The differences observed in clinical presentation across ages may inform symptom‐specific testing, screening, and management algorithms.
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI: 10.1056/nejmoa2034577
发表时间: 2020-12-31
期刊: The New England journal of medicine
影响因子: --
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者: C4591001 Clinical Trial Group
在B.1.617.2(Delta)和B.1.1.529(Omicron)变体占主导地位时,在实验室确认的SARS-COV-2感染的成年人中的临床特征和结果,2021年,以及2021年12月21日至2022年1月27日。
DOI: 10.15585/mmwr.mm7106e2
发表时间: 2022-02-11
期刊: MMWR. Morbidity and mortality weekly report
影响因子: --
作者:
Modes ME;Directo MP;Melgar M;Johnson LR;Yang H;Chaudhary P;Bartolini S;Kho N;Noble PW;Isonaka S;Chen P
通讯作者: Chen P
DOI: 10.1016/s2352-4642(22)00022-0
发表时间: 2022-04
期刊: The Lancet. Child & adolescent health
影响因子: --
作者:
Stephenson T;Pinto Pereira SM;Shafran R;de Stavola BL;Rojas N;McOwat K;Simmons R;Zavala M;O'Mahoney L;Chalder T;Crawley E;Ford TJ;Harnden A;Heyman I;Swann O;Whittaker E;CLoCk Consortium;Ladhani SN
通讯作者: Ladhani SN
DOI: 10.1111/tid.13772
发表时间: 2021-12-21
影响因子: 2.6
作者:
Yanis, Ahmad;Haddadin, Zaid;Halasa, Natasha B.
通讯作者: Halasa, Natasha B.
DOI: 10.1001/jamapediatrics.2021.2025
发表时间: 2021-06-11
期刊: JAMA PEDIATRICS
影响因子: 26.1
作者:
Chung, Erin;Chow, Eric J.;Chu, Helen Y.
通讯作者: Chu, Helen Y.